Allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimen for blastic plasmacytoid dendritic cell neoplasm patients in complete remission: a single center study

References

• Tsagarakis NJ, Paterakis G. Dendritic cell leukemia: a review. Curr Oncol Rep. 2020;22(6):55.
   PubMed Web of Science ®Google Scholar
• Li YX, Sun V, Sun W, et al. Blastic plasmacytoid dendritic cell neoplasm in children. Hematol Oncol Clin North Am. 2020;34(3):601–612.
   PubMed Web of Science ®Google Scholar
• Riaz W, Zhang L, Horna P, et al. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy. Cancer Control. 2014;21(4):279–289.
   PubMed Web of Science ®Google Scholar
• Pagano L, Valentini CG, Grammatico S, et al. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol. 2016;174(2):188–202.
   PubMed Web of Science ®Google Scholar
• Frankel AE, Woo JH, Ahn C, et al. Activity of SL-401, a targeted therapy directed to interleukin- 3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124(3):385–392.
   PubMed Web of Science ®Google Scholar
• Sullivan JM, Rizzieri DA. Treatment of blastic plasmacytoid dendritic cell neoplasm. Hematology Am Soc Hematol Educ Program. 2016;2016(1):16–23.
   PubMedGoogle Scholar
• Roos-Weil D, Dietrich S, Boumendil A, et al. Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2013;121(3):440–446.
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Reljic T, Murthy HS, et al. Allogeneic hematopoietic cell transplantation is an effective treatment for blastic plasmacytoid dendritic cell neoplasm in first complete remission: systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2018;18(11):703–709.
   PubMed Web of Science ®Google Scholar
• Aoki T, Suzuki R, Kuwatsuka Y, et al. Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood. 2015;125(23):3559–3562.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96(13):4075–4083.
   PubMed Web of Science ®Google Scholar
• Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–2919.
   PubMed Web of Science ®Google Scholar
• Harris AC, Young R, Devine S, et al. International, multicenter standardization of acute graft-versus-Host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant. 2016;22(1):4–10.
   PubMed Web of Science ®Google Scholar
• Jagasia MH, Greinix HT, Arora M, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21(3):389–401.
   PubMed Web of Science ®Google Scholar
• Deotare U, Hwan Kim DD, Michelis FV, et al. Allogeneic hematopoietic stem cell transplantions in blastic plasmacytoid dendritic cell neoplasm in first complete remission: an effective therapy for a rare disease. Leuk Lymphoma. 2016;57(8):1942–1944.
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, Al Malki MM, Deotare U, et al. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American Multicentre Collaborative Study. Br J Haematol. 2017;179(5):781–789.
   PubMed Web of Science ®Google Scholar
• Reimer P, Rüdiger T, Kraemer D, et al. What is CD4 + CD56+ malignancy and how should it be treated? Bone Marrow Transplant. 2003;32(7):637–646.
   PubMed Web of Science ®Google Scholar
• Dalle S, Beylot-Barry M, Bagot M, et al. Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol. 2010;162(1):74–79.
   PubMed Web of Science ®Google Scholar
• Pagano L, Valentini CG, Pulsoni A, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98(2):239–246.
   PubMed Web of Science ®Google Scholar
• Economides MP, Rizzieri D, Pemmaraju N. Updates in novel therapies for blastic plasmacytoid dendritic cell neoplasm (BPDCN). Curr Hematol Malig Rep. 2019;14(6):515–522.
   PubMed Web of Science ®Google Scholar
• Zhang X, Sun JW, Yang M, et al. New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm. Crit Rev Oncol Hematol. 2020;149:102928.
   PubMed Web of Science ®Google Scholar
• Wang SN, Wang XT, Liu MS, et al. Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents. Ann Hematol. 2018;97(4):563–572.
   PubMed Web of Science ®Google Scholar
• Montero J, Stephansky J, Cai TY, et al. Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL-2 and sensitive to venetoclax. Cancer Discov. 2017;7(2):156–164.
   PubMed Web of Science ®Google Scholar
• Wilson NR, Konopleva M, Khoury JD, et al. Novel therapeutic approaches in blastic plasmacytoid dendritic cell neoplasm (BPDCN): era of targeted therapy. Clin Lymphoma Myeloma Leuk. 2021;21(11):734–740.
   PubMed Web of Science ®Google Scholar
• Cheng W, Yu TT, Tang AP, et al. Blastic plasmacytoid dendritic cell neoplasm: progress in cell origin, molecular biology, diagnostic criteria and therapeutic approaches. Curr Med Sci. 2021;41(3):405–419.
   PubMed Web of Science ®Google Scholar
• Liu QF, Fan ZP, Zhang Y, et al. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia. Biol Blood Marrow Transplant. 2009;15(11):1376–1385.
   PubMed Web of Science ®Google Scholar
• Zhang R, Shi W, Wang HF, et al. Idarubicin-intensified haploidentical HSCT with GvHD prophylaxis of ATG and basiliximab provides comparable results to sibling donors in high-risk acute leukemia. Bone Marrow Transplant. 2017;52(9):1253–1260.
   PubMed Web of Science ®Google Scholar
• Chinnabhandar V, Tran S, Sutton R, et al. Addition of thiotepa to total body irradiation and cyclophosphamide conditioning for allogeneic hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2020;26(11):2068–2074.
   PubMed Web of Science ®Google Scholar
• Dulery R, Bastos J, Paviglianiti A, et al. Thiotepa, busulfan, and fludarabine conditioning regimen in T cell-replete HLA-haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25(7):1407–1415.
   PubMed Web of Science ®Google Scholar
• Chang YJ, Wang Y, Xu LP, et al. Haploidentical donor is preferred over matched sibling donor for pretransplantation MRD positive ALL: a phase 3 genetically randomized study. J Hematol Oncol. 2020;30:13–27.
   Google Scholar
• Lu Y, Zhao YL, Zhang JP, et al. Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status. Ann Hematol. 2020;99(12):2911–2925.
   PubMed Web of Science ®Google Scholar